Targeted Mass Spectrometry Suggests Beta-Synuclein as Synaptic Blood Marker in Alzheimer's Disease.
Sign Up to like & getrecommendations! Published in 2020 at "Journal of proteome research"
DOI: 10.1021/acs.jproteome.9b00824
Abstract: Synaptic degeneration is a major hallmark of Alzheimer's disease (AD) and the best pathological correlate of cognitive dysfunction. Synaptic markers are therefore a highly desired read-out for patient diagnosis and possible follow-up in clinical trials.… read more here.
Keywords: beta synuclein; mass spectrometry; blood marker; alzheimer disease ... See more keywords